Aequus Pharmaceuticals first quarter results show good progress in spite of the coronavirus pandemic
Doug Janzen, Aequus chairman and CEO said: We were pleased to see sales meet internal forecasts since February and we expect to continue our revenue growth trajectory going forward On March 1, 2021, Aequus Pharmaceuticals announced the commercial availability of its Evolve preservative-free lubricating eye drops for dry eye care
Aequus Pharmaceuticals Inc. (CVE:AQS) (OTCQB:AQSZF) has reported its financial results for the first quarter ended March 31, 2021, showing good progress in spite of the coronavirus (COVID-19) pandemic.
In the results statement, Doug Janzen, Aequus chairman and CEO, commented: “We had a productive start to 2021. Despite the many COVID-19 related restrictions that impacted all of Canada, our sales force continued to find creative ways to manage the business.